Cyto-Facto

Minamimachi, Japan

Cyto-Facto is a biotechnology company that develops and manufactures CAR-T cell therapies and mesenchymal stem cell products.

$7.6M raised

Apr 2024

Series A

Top Investors

Mizuho CapitalSMBC Venture CapitalMitsubishi CorporationMPower PartnersAsahi Kasei

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Cyto-Facto raised?

Cyto-Facto has raised $7.6M in total funding. The most recent round was Series A. The last funding was announced in April 2024.

Who are Cyto-Facto's investors?

Cyto-Facto's investors include Mizuho Capital, SMBC Venture Capital, Mitsubishi Corporation, MPower Partners, Asahi Kasei.

Where is Cyto-Facto headquartered?

Cyto-Facto is headquartered in Minamimachi, Japan.

What does Cyto-Facto do?

Cyto-Facto is a biotechnology company that develops and manufactures CAR-T cell therapies and mesenchymal stem cell products.

What stage is Cyto-Facto at?

Cyto-Facto is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated April 22, 2024.

MLA

"Cyto-Facto — Funding & Investors." VCBacked, April 22, 2024, https://www.vcbacked.co/company/cyto-facto. Accessed July 1, 2026.

APA

VCBacked. (2024). Cyto-Facto — Funding & Investors. Retrieved July 1, 2026, from https://www.vcbacked.co/company/cyto-facto

Wikipedia (cite web)

{{cite web |title=Cyto-Facto — Funding & Investors |url=https://www.vcbacked.co/company/cyto-facto |website=VCBacked |access-date=July 1, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated April 22, 2024.